Patient info Open main menu

Montelukast 4 mg granules in sachet – patient leaflet, side effects, dosage

Last updated: · Text from the MHRA, as of · About this document

Medicine status: Prescription only (POM) Details

Medicine strength:
4 mg
Contains active substance:
Similar medicines:

Patient leaflet - Montelukast 4 mg granules in sachet

1. What Montelukast is and what it is used for

What Montelukast is

Montelukast is a leukotriene receptor antagonist that blocks substances called leukotrienes.

How Montelukast works

Leukotrienes cause narrowing and swelling of airways in the lungs. By blocking leukotrienes, Montelukast improves asthma symptoms and helps control asthma.

When Montelukast should be used

Your doctor has prescribed Montelukast to treat your child’s asthma, preventing asthma symptoms during the day and night. • Montelukast is used for the treatment of 6 months to 5 year old

patients who are not adequately controlled on their medication and need additional therapy.

  • Montelukast may also be used as an alternative treatment to

    inhaled corticosteroids for 2 to 5 year old patients who have not recently taken oral corticosteroids for their asthma and have shown that they are unable to use inhaled corticosteroids. • Montelukast also helps prevent the narrowing of airways

    triggered by exercise for patients 2 years of age and older. Your doctor will determine how Montelukast should be used depending on the symptoms and severity of your child’s asthma.

What is asthma?

Asthma is a long-term disease.

Asthma includes:

  • difficulty breathing because of narrowed airways. This

    narrowing of airways worsens and improves in response to various conditions.

  • sensitive airways that react to many things, such as cigarette

    smoke, pollen, cold air, or exercise.

  • swelling (inflammation) in the lining of the airways. Symptoms of asthma include: Coughing, wheezing, and chest tightness.

2. What you need to know before your child takes Montelukast

Tell your doctor about any medical problems or allergies your child has now or has had.

Do not give Montelukast to your child

  • if he/she is allergic to montelukast or any of the other

    ingredients of this medicine (listed in section 6).

Warnings and precautions

Talk to your doctor or pharmacist before you give Montelukast to your child.

  • If your child’s asthma or breathing gets worse, tell your doctor

    immediately.

  • Oral Montelukast is not meant to treat acute asthma attacks. If

    an attack occurs, follow the instructions your doctor has given you for your child. Always have your child’s inhaled rescue medicine for asthma attacks with you.

  • It is important that your child take all asthma medications

    prescribed by your doctor. Montelukast should not be used instead of other asthma medications your doctor has prescribed for your child.

    • If your child is on anti-asthma medicines, be aware that if he/she develops a combination of symptoms such as flu-like illness, pins and needles or numbness of arms or legs, worsening of pulmonary symptoms, and/or rash, you should consult your doctor.
    • Your child should not take acetyl-salicylic acid (aspirin) or anti-inflammatory medicines (also known as non-steroidal anti-inflammatory drugs or NSAIDs) if they make his/her asthma worse.

Various neuropsychiatric events (for example behaviour and mood-related changes, depression and suicidality) have been reported in patients of all ages treated with montelukast (see section 4). There have also been reports of these symptoms continuing after treatment is stopped. If you develop such symptoms while taking montelukast or if these symptoms do not resolve after montelukast is stopped, you should contact your prescriber.

Children and adolescents

Do not give this medicine to children less than 6 months of age. There are different form(s) of this medicine available for paediatric patients under 18 years of age based on age range.

Other medicines and Montelukast

Tell your doctor or pharmacist if your child is taking or has recently been given or might be given any other medicines including those obtained without a prescription.

Some medicines may affect how Montelukast works, or Montelukast may affect how your child’s other medicines work. Tell your doctor if your child is taking the following medicines before starting Montelukast:

  • phenobarbital (used for treatment of epilepsy)
  • phenytoin (used for treatment of epilepsy)
  • rifampicin (used to treat tuberculosis and some other infections)

Montelukast with food and drink

Montelukast granules can be taken without regard to the timing of food intake.

Pregnancy and breast-feeding

This subsection is not applicable for the Montelukast 4 mg granules since they are intended for use in children 6 months to 5 years of age.

Driving and using machines

This subsection is not applicable for the Montelukast 4 mg granules since they are intended for use in children 6 months to 5 years of age, however the following information is relevant to the active ingredient, montelukast.

Montelukast is not expected to affect your ability to drive a car or operate machinery. However, individual responses to medication may vary. Certain side effects (such as dizziness and drowsiness) that have been reported with Montelukast may affect some patients’ ability to drive or operate machinery.

Montelukast contains sodium

This medicine contains less than 1 mmol sodium (23 mg) per sachet, that is to say essentially ‘sodium-free’.

3. How to take Montelukast

Always have your child take this medicine exactly as your doctor or pharmacist has told you. Check with your child’s doctor or pharmacist if you are not sure.

  • This medicine is to be given to a child under adult supervision.

    Your child should take Montelukast every evening. • It should be taken even when your child has no symptoms or if he/she has an acute asthma attack.

For children 6 months to 5 years of age:

The recommended dose is one sachet of Montelukast 4 mg granules to be taken by mouth each evening.

If your child is taking Montelukast, be sure that your child does not take any other products that contain the same active ingredient, montelukast.

How should I give Montelukast granules to my child?

This medicine is for oral use.

  • Do not open the sachet until ready to use
  • Montelukast granules can be given either:

    o directly in the mouth;

    o OR mixed with a spoonful of cold or room temperature soft food (for example, applesauce, ice cream, carrots and rice). Package leaflet: Information for the user Montelukast 4 mg granules in sachet

Black A/s : 210 x 360 mm

  • Mix all of the contents of the Montelukast granules into a

    spoonful of cold or room temperature soft food, taking care to see that the entire dose is mixed with the food. Be sure the child is given the entire spoonful of the granule/food mixture immediately (within 15 minutes). IMPORTANT: Never store any granule/food mixture for use at a later time.

  • Montelukast granules are not intended to be dissolved in liquid.

    However, your child may take liquids after swallowing the Montelukast granules.

  • Montelukast granules can be taken without regard to the timing

    of food intake.

If your child takes more Montelukast than he/she should

Contact your child’s doctor immediately for advice. There were no side effects reported in the majority of overdose reports. The most frequently occurring symptoms reported with overdose in adults and children included abdominal pain, sleepiness, thirst, headache, vomiting, and hyperactivity.

If you forget to give Montelukast to your child

Try to give Montelukast as prescribed. However, if your child misses a dose, just resume the usual schedule of one sachet once daily.

Do not give a double dose to make up for a forgotten dose.

If your child stops taking Montelukast

Montelukast can treat your child’s asthma only if he/she continues taking it.

It is important for your child to continue taking Montelukast for as long as your doctor prescribes. It will help control your child’s asthma.

If you have any further questions on the use of this medicine, ask your child’s doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

In clinical studies with Montelukast 4 mg granules, the most commonly reported side effects (may affect up to 1 in 10 people) thought to be related to Montelukast were:

  • diarrhoea
  • hyperactivity
  • asthma
  • scaly and itchy skin
  • rash

Additionally, the following side effects were reported in clinical studies with either Montelukast 10 mg film-coated tablets, Montelukast 5 mg or 4 mg chewable tablets:

  • abdominal pain
  • headache
  • thirst

These were usually mild and occurred at a greater frequency in patients treated with Montelukast than placebo (a pill containing no medication).

Serious side effects

Talk with your doctor immediately if you notice any of the following side effects with your child, which may be serious, and for which your child may need urgent medical treatment.

Uncommon: may affect up to 1 in 100 people

  • allergic reactions including swelling of the face, lips, tongue,

    and/or throat which may cause difficulty in breathing or swallowing

  • behaviour and mood related changes: agitation including

    aggressive behaviour or hostility, depression

  • seizure

Rare: may affect up to 1 in 1,000 people

  • increased bleeding tendency
  • tremor
  • palpitations

Very rare: may affect up to 1 in 10,000 people

  • combination of symptoms such as flu-like illness, pins

    and needles or numbness of arms and legs, worsening of pulmonary symptoms and/or rash (Churg-Strauss syndrome) (see section 2)

  • low blood platelet count
  • behaviour and mood related changes: hallucinations,

    disorientation, suicidal thoughts and actions

  • swelling (inflammation) of the lungs
  • severe skin reactions (erythema multiforme) that may occur

    without warning

  • inflammation of the liver (hepatitis)

    Other side effects while the medicine has been on the market Very common: may affect more than 1 in 10 people

    • upper respiratory infection

Common: may affect up to 1 in 10 people

  • diarrhoea, nausea, vomiting
  • rash
  • fever
  • elevated liver enzymes

Uncommon: may affect up to 1 in 100 people

  • behaviour and mood related changes: dream abnormalities, including nightmares, trouble sleeping, sleepwalking, irritability, feeling anxious, restlessness
  • dizziness, drowsiness, pins and needles/numbness
  • nosebleed
  • dry mouth, indigestion
  • bruising, itching, hives
  • joint or muscle pain, muscle cramps
  • bedwetting in children
  • weakness/tiredness, feeling unwell, swelling

Rare: may affect up to 1 in 1,000 people

  • behaviour and mood related changes: disturbance in attention, memory impairment, uncontrolled muscle movements

Very rare: may affect up to 1 in 10,000 people

  • tender red lumps under the skin, most commonly on your shins

    (erythema nodosum)

  • behaviour and mood related changes: obsessive-compulsive symptoms, stuttering

Reporting of side effects

If your child gets any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Montelukast

  • Keep this medicine out of the sight and reach of children.
  • Do not use this medicine after the expiry date which is stated on the sachet after EXP. The first two numbers indicate the month; the last four numbers indicate the year. The expiry date refers to the last date of that month.
  • Store in the original package in order to protect from light.
  • Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Montelukast contains

  • The active substance is montelukast. Each sachet of granules contains 4 mg Montelukast (as montelukast sodium).
  • The other ingredients are: Mannitol, hydroxypropylcellulose, and magnesium stearate.

What Montelukast looks like and contents of the pack

Montelukast 4 mg granules in sachet are White to off-white granules.

Packs of 28 sachets.

Marketing Authorisation Holder

Milpharm Limited

1 Roundwood Avenue

Stockley Park, Uxbridge

UB11 1AF

United Kingdom

Manufacturer

APL Swift Services (Malta) Limited

HF26, Hal Far Industrial Estate, Hal Far,

Birzebbugia, BBG 3000, Malta

Or

Milpharm Limited

1 Roundwood Avenue

Stockley Park, Uxbridge

UB11 1AF

United Kingdom

This leaflet was last revised in 06/2026.

Ref Ver: 01

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PL 16363/0675

Last revision stated in the text: June 2026 · MHRA data as of 13 October 2026

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Montelukast 4 mg granules in sachet

Prescription needed? Yes, prescription-only medicine (POM)
Active substance Montelukast
Strength 4 mg
Pharmaceutical form Oral granules
White to off-white granules.
How is it taken Oral
Excipients Mannitol, Hydroxypropylcellulose, Magnesium stearate
Is it available? Listed as available (NHS Dictionary of Medicines and Devices – not a record of current supplies)
Shelf life 3 years
Storage This medicinal product does not require any special
temperature storage conditions.
Store in the original package in order to protect from light.
Drug group (ATC) Leukotriene receptor antagonist
  1. R Respiratory system drugs
    1. R03 Drugs for obstructive airway diseases
      1. R03D Other systemic drugs for obstructive airway diseases
        1. R03DC Leukotriene receptor antagonists for obstructive airway diseases
          1. R03DC03 montelukast
Marketing authorisation PL 16363/0675 (first authorised 1 June 2022)
Marketing authorisation holder Milpharm Limited
Codes BNF 03030200

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 10.1.0 of 12 October 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.